1 / 1

Romiplostim(Nplate)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

NPLATE® (romiplostim) is a synthetic thrombopoietin receptor agonist that is primarily used to increase platelet counts in patients with thrombocytopenia. It is especially indicated for those with immune thrombocytopenia (ITP) who have not responded to other treatments such as corticosteroids, immunoglobulins, or splenectomy. Additionally, NPLATE® plays a vital role in improving platelet production in patients exposed to myelosuppressive radiation doses, helping to mitigate the risk of bleeding and promote platelet recovery.

The drug is administered subcutaneously and is dosed according to body weight. The response is monitored through regular platelet count assessments, and dose adjustments are made to achieve and maintain optimal platelet levels. However, treatment should be discontinued if no adequate response is observed after several weeks of therapy. Regular monitoring for adverse reactions, including thromboembolic events, is recommended during treatment with NPLATE®.

Generic name

Romiplostim(Nplate)

English name

Romiplostim

Alternative Names

Nplate

Drug prices

Indications

Immune Thrombocytopenia (ITP):

Adults with ITP who have insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Pediatric patients ≥1 year with ITP (≥6 months duration) refractory to standard therapies.

Treatment of thrombocytopenia in:

Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS):

To increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive radiation.

Therapeutic Target

Thrombopoietin (TPO) receptor agonist.

Active Ingredients

Romiplostim: An Fc-peptide fusion protein (peptibody) with no sequence homology to endogenous TPO.

Dosage form

INJECTION

specifications

125 mcg (NDC 55513-223-01). 250 mcg (NDC 55513-221-01). 500 mcg (NDC 55513-222-01).

Description

Structure: Recombinant Fc-peptide fusion protein produced in E. coli.

Excipients: L-histidine, mannitol, polysorbate 20, sucrose, HCl (pH 5).

Reconstitution: Requires Sterile Water for Injection; dilution with 0.9% NaCl for doses <23 mcg.

Dosage and Administration

ITP:

Initial Dose: 1 mcg/kg weekly (subcutaneous).

Adjustments:

Adults: Based on platelet counts.

Pediatrics: Adjust based on platelet counts and body weight (reassess weight every 12 weeks).

Maximum Dose: 10 mcg/kg weekly.

Discontinue if no response after 4 weeks at maximum dose.

HS-ARS:

Single Dose: 10 mcg/kg (subcutaneous) as soon as possible post-exposure.

Administration Notes:

Use syringes with 0.01 mL graduations for accuracy.

Reconstitution/Dilution: Follow Table 1 (vial-specific volumes for Sterile Water and NaCl).

CATEGORY NAVIGATION